BioXcel Therapeutics, Inc. (BTAI)
Stock Price:
$50.76 USD
0.88 (1.75%)
Updated Jul 14, 2020 12:55 PM EDT - Market open
Key Info
| Market Cap |
1.03B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-40.68M |
| Shares Out |
20.21M |
| EPS (ttm) |
-2.38 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 14, 2020 |
| Last Price |
$50.76 |
| Previous Close |
$49.88 |
| Change ($) |
0.88 |
| Change (%) |
1.75% |
| Day's Open |
49.73 |
| Day's Range |
48.44 - 51.89 |
| Day's Volume |
196,306 |
| 52-Week Range |
3.76 - 61.50 |
More Stats
| Market Cap |
1.03B |
| Enterprise Value |
946.71M |
| Earnings Date (est) |
Aug 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
20.21M |
| Float |
10.72M |
| EPS (basic) |
-2.35 |
| EPS (diluted) |
-2.38 |
| FCF / Share |
-1.80 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.24M |
| Short Ratio |
4.42 |
| Short % of Float |
21.29% |
| Beta |
2.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
14.51 |
| Revenue |
n/a |
| Operating Income |
-41.18M |
| Net Income |
-40.68M |
| Free Cash Flow |
-34.05M |
| Net Cash |
79.12M |
| Net Cash / Share |
3.91 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-40.81% |
| ROE |
-77.51% |
| ROIC |
1,062.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
7 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$91.29*
(79.86% upside)
Low
63.0
Current: 50.76
High
150.0
Target: 91.29
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -33.60 | -19.96 | -4.54 | -2.12 |
| Net Income | -32.97 | -19.27 | -4.54 | -2.12 |
| Shares Outstanding | 16.29 | 14.57 | 9.69 | 9.48 |
| Earnings Per Share | -2.02 | -1.32 | -0.47 | -0.22 |
| Operating Cash Flow | -27.28 | -13.51 | -2.20 | -1.29 |
| Capital Expenditures | -0.87 | -0.34 | - | - |
| Free Cash Flow | -28.15 | -13.85 | -2.20 | -1.30 |
| Cash & Equivalents | 32.43 | 42.57 | 0.89 | 0.00 |
| Total Debt | 1.03 | - | 0.37 | - |
| Net Cash / Debt | 31.40 | 42.57 | 0.52 | 0.00 |
| Assets | 36.39 | 43.55 | 1.36 | 0.01 |
| Liabilities | 9.50 | 4.66 | 2.34 | 0.33 |
| Book Value | 26.90 | 38.89 | -0.98 | -0.32 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
BioXcel Therapeutics, Inc. |
| Country |
United States |
| Employees |
27 |
| CEO |
Vimal D. Mehta |
Stock Information
| Ticker Symbol |
BTAI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BTAI |
| IPO Date |
March 8, 2018 |
Description
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.